Research programme: nerve-targeted gene therapy - Periphagen

Drug Profile

Research programme: nerve-targeted gene therapy - Periphagen

Alternative Names: NC 3; NE 2; NE2 Endomorphin; NG 2; NG2 GAD; NN1 Neurotrophin

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Diamyd Medical
  • Developer Diamyd Medical; Periphagen Holdings; University of Michigan
  • Class Gene therapies
  • Mechanism of Action GABA modulators; Glutamate decarboxylase stimulants; Nerve growth factor stimulants; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Erectile dysfunction; Glioma; Neuropathic pain; Peripheral nervous system diseases

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (Intradermal, Injection)
  • 04 Nov 2017 No recent reports of development identified for research development in Peripheral-nervous-system-diseases(Prevention, Chemotherapy-induced) in USA (Parenteral, Injection)
  • 12 Oct 2012 Preclinical development is ongoing for Neuropathic pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top